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Objectives: To evaluate the regenerative potential of human dental pulp stem cells 
(hDPSCs)	in	an	animal	model	of	stress	urinary	incontinence	(SUI).	SUI,	an	involuntary	
leakage	of	urine,	is	due	to	physical	stress	involving	an	increase	in	bladder	pressure	and	
a damage of external urethral sphincter affecting muscles and nerves. Conventional 
therapies	can	only	relieve	the	symptoms.	Human	DPSCs	are	characterized	by	pecu‐
liar stemness and immunomodulatory properties and might provide an alternative 
tool	for	SUI	therapy.
Materials and methods: In	vitro	phase:	hDPSCs	were	induced	towards	the	myogenic	
commitment	following	a	24	hours	pre‐conditioning	with	5‐aza‐2′‐deoxycytidine	(5‐











Conclusions: These promising data and further investigations on immunomodulatory 
abilities	of	hDPSCs	would	allow	to	make	them	a	potential	tool	for	alternative	thera‐
pies	of	SUI.
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1  | INTRODUC TION
Urinary	 incontinence	 (UI),	 defined	 as	 the	 involuntary	 leakage	 of	




Urinary incontinence arises from dysfunctions affecting the pel‐
vic	floor,	whose	physiology	 is	maintained	by	a	fine	balance	among	
bone,	muscle	and	nerve	tissues.
The three most common types of UI are stress urinary incon‐
tinence	 (SUI),	 urge	 urinary	 incontinence	 (UUI)	 or	 a	 combination	
of	 both,	 that	 is	 mixed	 urinary	 incontinence	 (MUI).	 Although	 SUI	
is	 the	most	prevalent	 type	 in	women,1 the symptoms of stress in‐
continence are associated with urethral hypermobility and intrinsic 
sphincter	deficiency.	While	the	former	 is	caused	by	a	weakness	 in	
the	 pelvic	 floor	 musculature,	 pelvic	 fascia	 and	 pubourethral	 liga‐
ments,	the	latter	is	caused	by	pudendal	nerve	damage	and	damage	
to	the	intrinsic	and	extrinsic	urethral	sphincter,	as	occurring	in	men	
after radical prostatectomy.2 These two injuries affecting striated 
muscle	and	nerve	fibres	are	strongly	correlated	with	the	SUI.3	For	
the prevention of male stress incontinence resulting from radical 
prostatectomy,	some	researchers	have	proposed	intraoperative	re‐
constructive techniques such as the posterior musculofascial recon‐
struction4 or the pubo‐prostatic ligament reconstruction.5
However,	surgical	approaches,	such	as	tension‐free	vaginal	tape,	
transobturator	 slings	 or	 pubovaginal	 slings,	 remain	 the	 gold	 stan‐
dards	for	SUI	treatment.	Most	of	these	strategies	apply	local	com‐
pression to the urethra in order to improve continence but do not 
correct	 the	underlying	muscle	and	nerve	pathology.	However,	not	
all patients can benefit from the surgery because the procedure‐re‐
lated	risks	(associated	with	the	patients’	clinical	comorbidities)	may	
outweigh the benefits of this therapy.6 The efficacy of pharmaco‐
therapy	for	SUI	has	been	disappointing.	Attempts	to	avoid	invasive	
surgery and morbidity have included the use of various injectable 
bulking	agents,	 including	polytetrafluoroethylene,	bovine	collagen,	
silicone	 particles,	 carbon	 beads	 and	 autologous	 fat	 or	 chondro‐




Regenerative medicine may provide an exciting means to fill the 
therapeutic gap by restoring and maintaining normal function via di‐
rect or indirect effects on injured tissues.
So	 far	 different	 stem	 cells	 sources,	 such	 as	 muscle‐derived	
stem	cells,	adipose	stem	cells,	bone	marrow	stem	cells	and	amniotic	
fluid	stem	cells,10 have been evaluated in different preclinical and 





munomodulatory properties and are able to differentiate towards 
different	 lineages.	 Previous	 findings	 demonstrated	 that	 hDPSCs	
are able to participate to the regeneration of skeletal muscle in 
Duchenne	Muscular	Dystrophy	(DMD)	and	peripheral	nerve	injury	
animal models after reaching the commitment towards myoblasts 
and	 Schwann	 cells,	 respectively.24,25	 Even	 though	 hDPSCs	were	
investigated	 in	 the	 regeneration	 of	 bladder	 smooth	muscle,	 less	
is	 known	about	 their	 application	 in	 animal	model	of	SUI.	To	 this	
regard,	the	aim	of	our	study	was	to	 investigate	whether	hDPSCs	
are able to restore the urethral sphincter to normal histology and 
function	in	female	rats	after	inducing	SUI	through	pudendal	nerve	
resection.
2  | MATERIAL S AND METHODS
2.1 | Isolation and immune selection and stemness 
properties of hDPSCs
The	study	was	approved	by	the	Comitato	Etico	Provinciale—Azienda	




cordance with the Declaration of Helsinki. Dental pulp was harvested 
from	the	teeth	and	underwent	enzymatic	digestion	by	using	a	diges‐
tive	solution,	consisting	 in	3	mg/mL	type	 I	collagenase	plus	4	mg/
mL	dispase	 in	α‐MEM. Pulp was then filtered onto 100 μm	Falcon	
Cell	Strainers,	 in	order	to	obtain	a	cell	suspension.	Cell	suspension	
was then plated in 25 cm2 culture flasks and expanded in culture 
medium [α‐MEM	supplemented	with	10%	foetal	bovine	serum	(FBS),	
2	mmol/L	l‐glutamine,	100	U/mL	penicillin,	100	μg/mL	streptomycin]	
at 37°C and 5% CO2. Non‐adherent cells were discarded and hDP‐
SCs	were	expanded	upon	80%	confluency.	Following	cell	expansion,	
human	 DPSCs	 underwent	 magnetic	 cell	 sorting	 through	 MACS®	
separation	 kit.	 Particularly,	 hDPSCs	were	 selected	 for	 the	expres‐
sion	of	STRO‐1	and	c‐Kit	surface	antigens	by	using	mouse	IgM	anti‐
STRO‐1	 and	 rabbit	 IgG	 anti‐c‐Kit	 primary	 antibodies	 (Santa	Cruz),	






human	 HLA‐DP‐DQ‐DR	 (BD	 Biosciences)	 and	 rabbit	 anti‐human	
FasL	(Santacruz,	Santa	Cruz	Biotechnology,	Inc)	antibodies.
2.2 | Osteogenic and adipogenic differentiation
The	 mesenchymal	 ability	 was	 evaluated	 by	 inducing	 hDPSCs	 to‐
wards osteogenic and adipogenic lineages at passage 3. Osteogenic 
differentiation	 of	 hDPSCs	was	 induced	 for	 3	weeks	 as	 previously	
described.27 Cells were seeded at approximately 3 × 103 cells/
cm2 on culture dishes in osteogenic medium (culture medium sup‐
plemented	with	5%	FCS,	100	μmol/L	2P‐ascorbic	acid,	100	nmol/L	
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dexamethasone,	 10	 mmol/L	 β‐glycerophosphate)	 for	 4	 weeks.	
Mineralized	 extracellular	 matrix	 deposition	 was	 assessed	 through	
Alizarin	Red	staining.
Adipogenic	 differentiation	 was	 performed	 as	 previously	 de‐
scribed.28	hDPSCs	were	seeded	on	24‐well	plates	at	a	cell	density	
of 2 × 104cells/cm2.	 Subconfluent	 cultures	were	 incubated	 in	 the	
adipogenic	medium	(culture	medium	containing	0.5	mmol/L	 isobu‐
tyl‐methylxanthine,	 1	 μmol/L	 dexamethasone,	 10	 μmol/L	 insulin,	
200 μmol/L	 indomethacin,	 50	 mg/mL	 gentamicin)	 for	 3	 weeks.	
Medium	was	changed	every	3	days.	Afterwards,	cells	were	evaluated	
for the formation of lipid droplets by means of oil red O staining. 
Undifferentiated cells were used as negative control.
2.3 | Myogenic differentiation of hDPSCs
In order to evaluate the myogenic differentiation potential of hDP‐
SCs,	 4000	 cells/cm2 were seeded in expansion medium consisting 
in	 DMEM‐High	 Glucose	 (DMEM‐HG)	 plus	 10%	 FBS,	 2	 mmol/L	 L‐
glutamine,	100	U/mL	penicillin	and	100	μg/mL	streptomycin.	After	




100 μg/mL	 streptomycin.	 After	 24	 hours	 of	 demethylating	 treat‐
ment,	hDPSCs	were	processed	for	evaluation	of	early	myogenic	tran‐
scription	factors	(Pax7	and	myogenin)	by	real‐time	PCR	and	Western	
Blot	 analysis.	 Besides	 hDPSCs	 were	 maintained	 for	 in	 myogenic	






below. Differentiated C2C12 cells were used as positive controls.
2.4 | Real‐time PCR analysis
Human	 DPSC	 cells	 were	 homogenized,	 and	 total	 RNA	 was	 ex‐
tracted	and	purified	using	the	PureLink	RNA	columns	(Thermo	Fisher	
Scientific).	 cDNA	 synthesis	 was	 performed	 by	 using	 Maxima	 First	
Strand	 cDNA	Synthesis	Kit	with	DNase	 I	 treatment	 (Thermo	Fisher	
Scientific).	Quantitative	 real‐time	PCRs	were	performed	using	SYBR	
Green	Master	mix	 (Bio‐Rad)	on	CFX	Connect	Real‐time	PCR	 instru‐
ment	 (Bio‐Rad),	 with	 the	 following	 oligonucleotides:	 h	 RPLP0	 (F:	
TACACCTTCCCACTTGCTGA,	R:	CCATATCCTCGTCCGACTCC);	h	Pax7	
(GAGGATGAAGCGGACAAGAA,	 R:	 TCAGTGGGAGGTCAGGTT);	 h	
Myogenin	(F:	GGTGCCCAGCGAATGC	R:	TGATGCTGTCCACGATGGA).	
Relative quantification was calculated from the ratio between the 
cycle	number	 (Ct)	at	which	the	signal	crossed	a	threshold	set	within	
the logarithmic phase of the given gene and that of the reference 
hRPLP0.	Mean	values	of	 the	duplicate	 results	of	 three	 independent	





viously described.25	 Briefly,	 30	 µg	 of	 protein	 extract	 per	 sample	
was	 quantified	 by	 a	 Bradford	 Protein	Assay	 (Bio‐Rad),	 underwent	
SDS‐polyacrylamide	gel	electrophoresis	and	was	then	transferred	to	
PVDF	membranes.	The	following	antibodies	were	used:	mouse	anti‐
Pax7	 (DSHB,	 Hybridoma	 Bank),	 mouse	 anti‐myogenin	 and	 rabbit	
anti‐desmin	 (Sigma‐Aldrich),	 diluted	 1:1000	 in	 Tris‐buffered	 saline	
Tween	20	plus	2%	BSA	and	3%	non‐fat	milk.	Membranes	were	then	
incubated for 30 minutes at room temperature with HRP‐conjugated 
anti‐mouse	 and	 anti‐rabbit	 secondary	 antibodies,	 diluted	 1:3000.	
Membranes	were	 then	visualized	using	ECL	 (enhanced	chemilumi‐
nescence,	 Amersham,	 United	 Kingdom).	 Anti‐actin	 antibody	 was	




background and of control actin band.26
2.6 | Induction of urinary incontinence in animal 
model after pudendal nerve transection
All	 experimental	 protocols	 were	 reviewed	 by	 the	 Local	 Animal	
Ethics	Committee	(OPBA),	University	of	Modena	and	Reggio	Emilia,	
Italy,	and	approved	by	Ministero	della	Salute	(authorization	number	




drochloride	 (Ketavet	 100®;	Farmaceutici	Gellini)	 plus	 xylazine	hy‐
drochloride	 (Rompun®;	Bayer	AG)	by	 intraperitoneal	 injection	and	
generation of incompetent urethral sphincter model was carried out 
according	to	Kim	et	al10 using a bilateral pudendal nerve transection 
technique.	Briefly,	a	lower	midline	abdominal	incision	was	made,	and	
the bladder and urethra were exposed. The pudendal nerve on each 
side was identified and transected with microsurgical scissors under 
stereomicroscopic	magnification.	 Laparotomy	was	 closed	 in	 layers	
with absorbable 4 to 0 vicryl sutures.
2.7 | hDPSCs injection
One	week	after	generation	of	SUI,	animals	were	anesthetized,	and	
the bladder and the urethra were exposed by a lower abdominal in‐
cision.	Approximately	1	x	106	hDPSCs	preconditioned	with	5‐AZA	
for	 24	 hours,	were	 resuspended	 in	 10	μL	 of	 PBS	 1X	 and	 injected	
bilaterally in the external sphincter of each animal (5 x 105 cells 
for	each	side,	at	 the	 three	and	nine	o'clock	area),	by	using	a	50	μl 
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(c)	 Pudendal	 nerve	 transection	 rats	 with	 hDPSCs	 injection	 (cell+;	
n	=	8).	Animals	were	sacrificed	4	weeks	after	cell	injection.
2.8 | Measurement of leak point pressure (LPP)
Four	weeks	 after	 the	 injection	 of	 hDPSCs,	 urodynamic	 functional	
test	 was	 performed	 to	 measure	 the	 leak	 point	 pressure	 (LPP)	 in	
order to evaluate the functional recovery of urethral sphincter in 
the	three	experimental	groups.	As	previously	described	by	Kim	et	al,	
before	measuring,	rats	were	anesthetized,	and	the	spinal	cord	was	
transected at the T9‐T10 level to abrogate reflex bladder activity in 
response to increasing intravesical pressure although without inter‐
fering with the spinal continence reflexes of the bladder neck and 
urethra.10	Under	general	anaesthesia,	 the	bladder	was	exposed	by	
a	midline	incision.	A	suprapubic	PE‐50	bladder	catheter	solidarized	
to the bladder wall was placed and sutured with prolene 4‐0. The 
abdominal wall and the skin were then sutured in two layers. The 
suprapubic catheter was then connected by means of a three‐way 
valve,	either	to	a	pressure	transducer	(P300	type,	Grass	Instruments)	
or	to	a	syringe	pump	(100	type,	KD	Scientific).	The	transducer	was	
then	 linked	 to	 an	 amplifier	 (MT	9500	 type,	Astro‐Med,	 Inc)	 and	 a	
computer	to	record	pressure	data.	Subsequently,	rats	were	fixed	to	a	
support and placed in vertical position.
After	 a	 30	minutes	 period	 of	 accommodation	 to	 the	 filling	 of	
0.3 cc (which represents half of the bladder capacity in a rat weigh‐
ing	200	g),	 the	bladder	was	 filled	with	physiological	 solution	 (at	 a	
speed	of	5	cc/h)	in	order	to	simulate	the	bladder	filling	and	the	fol‐
lowing increased pressure. Bladder pressure was increased in steps 
in 1‐ to 3‐cm H2O steps from 0 cm H2O upwards until visual identifi‐
cation of the loss of urine. The pressure recorded at the point of loss 
was	taken	as	LPP.	Subsequently,	bladder	pressure	was	reduced	until	
ceasing	of	urine	leakage.	The	average	of	three	consecutive	LPP	re‐
cords was taken as a reference measurement for each animal. Values 
were expressed as mean ± standard deviation.
2.9 | Immunofluorescence analysis of stemness 
markers and myogenic differentiation in vitro
Immunofluorescence	analyses	were	carried	out	on	hDPSC	to	con‐
firm	the	immune	selection	against	c‐Kit	and	STRO‐1	and	to	evalu‐
ate the myogenic commitment after in vitro induction. Cells were 










bated for 1 hour at room temperature with the secondary antibod‐
ies	diluted	1:200	 in	PBS	containing	3%	BSA	 (donkey	anti‐mouse	




with the primary antibody were used as negative controls.26	 As	
formerly	 described,	 the	 multi‐labelling	 immunofluorescence	 ex‐
periments were carried out avoiding cross‐reactions between 





2.10 | Histological, morphometrical and 
immunohistochemical analyses in vivo





each experimental group were obtained. Routine haematoxylin/
eosin	staining	was	performed,	in	order	to	analyse	the	morphological	
details of the tissues. The extent of fibrosis in the urethral sphinc‐
ter	area	was	determined	by	using	Masson's	trichrome	staining,	ac‐
cording	 to	 the	 manufacturer's	 instructions	 (Masson's	 Trichrome	
stain	 kit;	 Sigma‐Aldrich).	 Images	 of	 the	 histological	 samples	were	
obtained	 with	 a	 Nikon	 Labophot‐2	 optical	 microscope	 equipped	
with	a	DS‐5Mc	CCD	colour	camera.	Morphometrical	analyses	were	
performed	by	 ImageJ	software	on	 three	slides	per	animal	per	ex‐
perimental	 group,	 5	 weeks	 after	 pudendal	 nerve	 transection.	 In	
particular,	the	thickness	of	the	striated	sphincter	was	measured	to	
evaluate whether muscular atrophy reversion occurred; the per‐
centage of fibrosis was calculated with respect to the total sphinc‐
ter	area.	Vascularization	of	the	injected	sphincters	was	measured	by	




by	 immunofluorescence	 and	 immunohistochemical	 analyses,	 as	
described	above,	and	the	following	primary	antibodies	were	used:	
mouse	 anti‐human	 mitochondria	 (hMit,	 1:100;	 Millipore),	 rabbit	
anti‐myosin	 heavy	 chain	 (myo,	 1:100;	 Sigma‐Aldrich),	 rabbit	 anti‐




used:	 goat	 anti‐rabbit	 Alexa488,	 goat	 anti‐mouse	Alexa488,	 goat	
anti‐rabbit	 546	 (Life	 Technologies).	 Immunohistochemistry	 with	













3.1 | Immune selection of hDPSCs and stemness 
evaluation
Following	 the	double	 immune‐magnetic	cell	 sorting,	hDPSCs	were	
stained	 for	c‐Kit	and	STRO‐1	surface	markers.	Almost	all	 the	cells	
showed a fibroblast‐like morphology and labelled positive for both 









After	 3	 weeks	 of	 osteogenic	 induction,	 deposition	 of	 mineralized	
extracellular	matrix	was	clearly	detected	through	Alizarin	Red	stain‐
ing	 in	 differentiated	 hDPSCs.	 Osteogenic	 commitment	 was	 also	
confirmed	 by	 Alkaline	 Phosphatase	 assay	 (Figure	 1C).	 Oil	 red	 O	




3.2 | Myogenic differentiation in vitro
When	 hDPSCs	 were	 cultured	 in	 myogenic	 medium,	 following	








with	 respect	 to	 undifferentiated	 hDPSCs	 (Figure	 2A).	Moreover,	
Western	blot	 analysis	 revealed	 that	 the	demethylating	 treatment	
induced	the	expression	of	myogenic‐related	markers,	Pax7	and	my‐
ogenin,	when	 compared	 to	untreated	hDPSCs	 (Figure	2B).	 These	
data	were	confirmed	by	immunofluorescence	analysis	(Figure	2C).	
After	3	weeks	of	culture	with	myogenic	medium,	hDPSCs	showed	
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the formation of multinucleated syncitia expressing the typical late 
myogenic	markers	myosin	 and	 desmin	 (Figure	 2D).	Western	 blot	
analysis	 of	 desmin	 confirmed	 that	 hDPSCs	 committed	 towards	
myogenic	 lineage,	 showing	 a	 statistically	 significant	 increase	 of	
desmin	 expression	 in	 comparison	 with	 undifferentiated	 hDPSCs	
(**P	<	.01)	(Figure	2E).
3.3 | Histological and histomorphometric analyses
In	order	to	evaluate	the	urethral	sphincter	regeneration,	serial	sec‐
tions from urethra specimens harvested 5 weeks after pudendal 
nerve	 transection	were	stained	by	H&E	and	Masson's	 trichrome.	
Histological	 analysis	 of	 H&E	 stain	 showed	 relevant	 differences	
in the arrangement of striated fibres of external urethral sphinc‐
ter	 among	 the	 three	 experimental	 groups,	with	Cell	 +	 group	 ex‐
hibiting	 a	 histological	 organization	 resembling	 the	 control	 group	
(Figure	3A).	Moreover,	in	the	experimental	group	Cell‐,	H&E	stain‐
ing showed the presence of fibrotic tissue spread through the 




hand,	 Cell	 +	 group	 showed	 an	 appreciable	 reduction	 of	 fibrosis	
in parallel with an ongoing rearrangement of the striated sphinc‐
ter	 area,	 as	 shown	 by	magnification	 images	 in	 Figure	 3A.	 Based	
on	 these	 observation,	 histomorphometric	 analyses	 were	 carried	
out in order to measure the striated sphincter thickness and the 
fibrosis	 area.	As	 reported	 in	 histograms,	 the	 experimental	 group	
Cell	+	showed	statistically	significant	higher	thickness	of	striated	









F I G U R E  2   Myogenic commitment and 
differentiation	of	hDPSCs.	A,	Real‐time	











after 3 wk of differentiation. Higher 
magnification reported on the right 
shows the presence of multinucleated 
syncitia.	E,	The	expression	of	desmin	was	
evaluated	by	Western	Blot	analysis	after	
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3.4 | Engraftment of hDPSCs in striated urethral 
sphincter and promotion of vascularization
Five	weeks	after	 the	bilateral	 transection	of	pudendal	nerve,	 immu‐




ing with anti‐myosin antibody allowed to identify the muscular compo‐
nent.	The	hMit	labelling	identified	the	presence	of	hDPSCs	localized	
in	the	peripheral	area	of	the	tissue,	specifically	in	the	striated	muscle	
fibres	of	urethral	sphincter.	Moreover,	hMit+ cells were also detected 







higher number of vasa when compared to Cell‐ group (***P	<	 .001).	
Data	demonstrate	that	the	number	of	vasa	observed	in	Cell	+	group	
was	close,	although	slightly	lower,	to	control	group.
Immunofluorescent and immunohistochemical labelling against 
hMit show areas with hMit+ cells arranging to form structures re‐
sembling	vessels	in	the	urethral	sphincter	(Figure	4C).
3.5 | Human DPSCs home to the injured nerve
Stress	urinary	incontinence	animal	model	was	created	by	transect‐
ing	 the	pudendal	nerve,	which	 subsequently	produced	 the	muscle	
atrophy	mimicking	the	pathophysiology	of	SUI.




confocal immunofluorescence analysis confirmed the presence of 
partial and discontinuous alignment of regenerating fibres as shown 
by	the	positive	staining	for	Neurofilament	heavy.	Moreover,	in	trans‐
verse	 sections	 the	presence	of	human	PCNA+ cells was observed. 
These	data	 suggest	 the	possible	 role	of	hDPSCs	 in	homing	 to	 the	
F I G U R E  3   Histological and 
histomorphometric	analyses.	A,	
Histological	analysis	by	H&E	staining	
of urethral sphincter performed in all 
experimental	groups.	Masson's	trichrome	
staining showing fibrosis distribution 
through the whole urethral sphincter 
section.	Scale	bar:	100	μm.	B,	Histograms	
represent histomorphometric evaluations 
of striated sphincter thickness and the 
percentage of fibrosis area in the three 
experimental	groups.	C,	Histograms	
report	the	LPP	obtained	by	urodynamic	
evaluation in each experimental group. 
In	any	case,	values	were	expressed	as	
mean	±	SD;	*P	<	.05,	**P	<	.01,	***P < .001 
vs	Cell‐	group.	ANOVA	followed	by	
Newman‐Keuls	post	hoc	test
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injured nerve and their contribution in promoting nerve regenera‐
tion	(Figure	5C).
4  | DISCUSSION
Urinary	 incontinence	 (UI),	 occurring	 as	 an	 involuntary	 leakage	 of	
urine,	 originates	 from	 the	 impairment	 of	 striated	muscle	 function	
in	 the	urethra,	due	 to	stretch,	 torn	or	crush	of	pudendal	nerve.	 In	




These	 factors	 are	 the	 basis	 of	 tissue	 damage,	 both	 muscular	 and	
nervous,	 which	 leads	 to	 alteration	 of	 the	 sphincter	 function.	 The	
evaluation of the presence and degree of incontinence must be done 





urodynamic	testing,35 pad testing36 and imaging.37
F I G U R E  4  Histointegration	of	hDPSCs.	
A,	Transverse	sections	of	urethral	




arrowhead indicating the presence of hMit 
+	cells	surrounding	vessels	like	structures.	
Magnification	of	the	inset	(white	square)	
highlights muscle fibres contemporarily 
labelled against human mitochondria 










immunohistochemistry analyses of hMit 
performed	in	Cell	+	and	Cell‐	groups.	
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In	clinical	practice,	urinary	incontinence	is	often	associated	with	
multiple	comorbidity	conditions.	For	this	reason,	non‐surgical	thera‐
pies are generally used first.
These may consist in correction of underlying diseases associ‐
ated with incontinence38	 (ie	 diabetes,	 neurological	 and	 cognitive	
diseases,	sleep	disorders),	 treatment	of	constipation,39 lifestyle in‐
terventions40‐42	 (ie	 weight	 loss,	 cessation	 of	 smoking,	 increase	 in	








In	 cases,	 where	 the	 SUI	 cannot	 be	 resolved	 with	 the	 treat‐
ments	 listed	 above,	 surgery	 remains	 the	 therapeutic	 option.	 The	
surgeons’ experience performing these procedures might influence 
the results.47 The therapeutic options range from the application of 
mid‐urethral slings to the open or laparoscopic or robotic colposus‐
pension,48 to the injection of bulking agents49 and the placement of 
artificial sphincters.50	Furthermore,	as	a	result	of	radical	prostatec‐
tomy,	the	repair	with	fibrous	tissue	 is	frequent,	which	could	cause	
these devices to be difficult to use and ineffective.
It is important to underline how the slings in women are tension‐
free,	while	in	men	these	can	result	in	decubitus	at	urethral	level,	with	
the	risk	of	erosions.	Consequently,	conventional	therapies	including	
pharmacology and surgery approaches offer appreciable results al‐
though they do not provide a complete resolution of the disease. 
Indeed,	 despite	 the	 high	 number	 of	 available	 procedures,	 not	 all	
patients	can	benefit	from	surgery,	because	the	risks	related	to	the	
procedure	 (associated	with	 patients’	 comorbidities)	may	 outweigh	
the benefits of this therapy.51	For	several	years,	cell	therapy	based	
regenerative medicine has been investigated as a valid alternative to 
the normal therapeutic options in order to reach the resolution of 
the pathophysiology by regenerating the injured tissue.52
Currently,	 the	 use	 of	 stem	 cells	 might	 represent	 an	 appealing	
alternative to restore urethral sphincter continence for the treat‐
ment	 of	 SUI.	 Up	 to	 now,	 many	 different	 stem	 cells	 sources	 have	
been	investigated	for	their	potential	application	to	SUI.10‐17,21,23,53‐




in the regeneration of striated muscle atrophy induced by a primary 
nerve	 injury.	To	this	regard,	 the	model	of	pudendal	nerve	transec‐
tion,	which	 triggers	 the	muscle	atrophy	 resulting	 in	urinary	 incon‐
tinence,	 represents	a	 suitable	experimental	approach	 to	study	 the	
potential	application	of	hDPSCs	in	the	treatment	of	SUI.
Data demonstrate that after 3 weeks of myogenic induction in 
vitro	 sorted	hDPSCs	were	 able	 to	differentiate	 towards	myogenic	
commitment by forming multinucleated syncytia and by express‐
ing	 late	myogenic	markers.	Noteworthy,	 the	 use	 of	 demethylating	
agent	5‐Aza	for	24	hours	was	able	to	induce	the	expression	of	the	
early markers such as Pax7 and myogenin. This approach was used 
as pre‐conditioning method prior to stem cells injection in rat ure‐
thral	sphincter.	As	a	matter	of	fact,	immunofluorescence	analysis	of	
Cell	 +	 group	 demonstrated	 that	 the	majority	 of	 human	 stem	 cells	
were	entrapped	in	striated	urethral	sphincter.	Interestingly,	we	no‐
ticed that after treatment a considerable reduction of fibrosis oc‐
curred in parallel with the recovery of muscle atrophy. This process 
might	be	sustained	by	the	contribution	of	hDPSCs	either	in	forming	
new syncytia or in surrounding vessels. These events are known to 
be primary in supporting the reduction of fibrosis process.57	Indeed,	
vascularization	 promotion	 is	 a	 well‐documented	 ability	 character‐
izing	hDPSCs24,58,59	which	does	not	 relate	 to	 tumorigenesis,	being	
instead	 important	 for	 regeneration.	 As	 formerly	 demonstrated	 by	
Sun	et	al,60	 vascularization	proved	 to	be	a	 favourable	condition	 in	
supporting the urethral regeneration. The regeneration of muscular 
component only would provide a transient/temporary recovery of 
the	urinary	continence.	Interestingly,	our	findings	revealed	the	pres‐
ence	of	hDPSCs	not	only	in	the	injection	tissue	but	also	in	transected	
F I G U R E  5   Integration	of	hDPSCs	
into	the	injured	nerve.	A,	H&E	staining	of	
a cross section highlights the pudendal 
nerve.	B,	immunofluorescence	staining	
against	neurofilament	heavy	(NFH,	green)	




the regenerating pudendal nerve. Nuclei 
were	counterstained	with	DAPI.	Scale	bar:	
50 μm
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injured	 nerve	 fibres,	 thus	 confirming	 previous	 evidence	 from	 our	
group	 regarding	 the	 capability	of	 hDPSCs	 to	 sustain	nerve	 regen‐
eration. It is important to highlight that muscle atrophy is a second‐
ary condition of pudendal nerve injury10;	 therefore,	 a	 cell	 therapy	
restoring either muscle trophism or supporting nerve repair would 
represent	a	suitable	tool	for	the	treatment	of	SUI.	In	consideration	
of our results and according to previous findings that demonstrated 
the low immunogenic human dental pulp stem cells and their ability 
to modulate the immune system in vitro by direct cell‐cell contact or 
by	secreting	different	soluble	factors	under	allogeneic	condition,	the	
next step might be a deeper investigation of the immunomodulatory 
pathway in vivo.
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